ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
980K |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
300K |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
131K |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Stock Options |
31.9K |
|
|
Aug 12, 2024 |
Directly held by BP Directors, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Stock Options |
15K |
|
|
Aug 12, 2024 |
Directly held by Aaron G.L. Fletcher |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Convertible Note |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Clinical Opportunity Fund, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series A Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund I, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series A Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund I QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest I, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest I, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest III, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |